Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

About neratinib and "other" HER2-targeting therapies.
PR from Daiichi Sankyo, Puma Biotechnology and Memorial Sloan Kettering Cancer Center (MSK) to explore the combination of Daiichi Sankyo’s investigational antibody drug conjugate DS-8201 and Puma Biotechnology’s irreversible pan-HER tyrosine kinase inhibitor neratinib (NERLYNX®) in HER2-mutated or HER2-positive solid tumors. But what else was interesting is that they will look at 'other HER2-targeting therapies'

“Since early clinical data suggest that DS-8201 may have activity beyond breast and gastric cancers, the archetype HER2-driven tumors, we are interested in studying this asset on a molecular level as well as in combination with other HER2-targeting agents,” said Tom Held, Vice President, Global Head, Antibody Drug Conjugate Task Force, Daiichi Sankyo. “In this collaboration, we are examining whether combining DS-8201 and neratinib, with its specific covalent binding to the HER2 receptor and associated increased internalization, is a rational combination therapy strategy to pursue.

3 things stick in my mind 1) they are using in vitro tests so results should be generated relatively quickly and I think you would expect to hear something next year, 2) you would expect results on "other" HER2-targeting therapies to be included. Hopefully, one of the 'others' is pozi. And 3) this made me think of basket studies that Dr. Raj alluded to in the last quarterly CC.

Since early clinical data suggest that DS-8201 may have activity beyond breast and gastric cancers, the archetype HER2-driven tumors

http://www.businesswire.com/news/home/20171212006311/en/